Clal Biotechnology reported ILS121.41M in Equity Capital and Reserves for its fiscal quarter ending in December of 2023.





Equity Capital And Reserves Change Date
Arca Biopharma USD 486.72M 17.72M Mar/2026
aTyr Pharma USD 57.93M 82.05M Mar/2026
Bio Path USD -8.49M 482K Mar/2026
Brainstorm Cell Therapeutics USD -11.01M 1.02M Mar/2026
Cara Therapeutics USD 20.95M 6.92M Dec/2025
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 102.73M 58.9M Dec/2025
Immunic USD 151.23M 157.91M Mar/2026
Infinity Pharmaceuticals USD -37.41M 9.08M Jun/2023
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
RedHill Biopharma USD -4.41M 271K Jun/2025
TherapeuticsMD USD 27.67M 990K Jun/2024